| 31.85 1.041 (3.38%) | 03-09 14:41 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 37.64 | 1-year : | 38.94 |
| Resists | First : | 32.22 | Second : | 33.34 |
| Pivot price | 31.91 |
|||
| Supports | First : | 30.43 | Second : | 25.31 |
| MAs | MA(5) : | 31.2 |
MA(20) : | 31.95  |
| MA(100) : | 31.13 |
MA(250) : | 26.33 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 25.3 |
D(3) : | 19.9 |
| RSI | RSI(14): 49.1 |
|||
| 52-week | High : | 37 | Low : | 17.68 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IBRN ] has closed above bottom band by 47.4%. Bollinger Bands are 5.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 31.11 - 31.29 | 31.29 - 31.48 |
| Low: | 29.93 - 30.13 | 30.13 - 30.34 |
| Close: | 30.44 - 30.78 | 30.78 - 31.15 |
The iShares Neuroscience and Healthcare ETF seeks to track the investment results of an index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience.
Mon, 09 Mar 2026
Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures - Benzinga
Mon, 02 Mar 2026
Avoiding Lag: Real-Time Signals in (IBRN) Movement - Stock Traders Daily
Thu, 13 Nov 2025
Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month - Nasdaq
Thu, 18 Jul 2024
Where to Invest in Health Trends - Bloomberg.com
Wed, 31 Jan 2024
Neuralink Stock Price, Symbol: How to Invest in Neuralink IPO? - CoinCodex
Wed, 22 Mar 2023
Healthcare Stocks List 2026: Best Publicly Traded Companies - Bullish Bears
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|